semaglutide alzheimer's trial GLP-1 Pill Fails to Slow Alzheimer's Progression in Clinical Trial

Two of the most anticipated studies this year—large-scale, randomized, controlled, and double-blinded trials of the popular obesity and diabetes drug semaglutide for Alzheimer's disease—have unfortunately ended in a dud. An oral version

21.41

★★★★☆4.8 (126)

Semaglutide may reduce Alzheimer's risk in diabetics

20.80

★★★★★4.9 (98)

Topline results from the phase 3 EVOKE and EVOKE+ studies of oral semaglutide in early Alzheimer's disease (AD) show that the trials did not meet their primary endpoints, Novo Nordisk announced. The

22.44

★★★★★5.0 (157)

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

22.55

★★★★★4.7 (84)

Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant

22.03

★★★★★4.9 (203)

Observational data indicated that semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in individuals with type 2 diabetes. Read more at the link in our bio. #ozempic #Semaglutide #

22.64

★★★★★5.0 (176)

Semaglutide fails to slow progression of Alzheimer's in highly anticipated trials, Novo Nordisk says

28.22

★★★★★4.8 (132)